Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE TrialGlobeNewsWire · 4 days ago
Moleculin Announces Reverse Stock SplitGlobeNewsWire · Oct 16, 2026
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth SummitGlobeNewsWire · Oct 7, 2026
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data ReadoutGlobeNewsWire · Sep 29, 2026
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicineGlobeNewsWire · Sep 28, 2026
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACRGlobeNewsWire · Sep 25, 2026Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$31.00 | -$28.00 | Beat |
| May 12, 2026 | -$33.80 | -$3.54 | Beat |
| Mar 20, 2026 | -$122.27 | -$57.00 | Beat |
| Nov 14, 2025 | -$4.00 | -$17.02 | Miss |
| Aug 12, 2025 | -$9.75 | -$12.25 | Miss |
| May 14, 2025 | -$14.20 | -$13.80 | Beat |